Immupharma PLC Conversion of Convertible Security (0867G)
November 23 2020 - 2:00AM
UK Regulatory
TIDMIMM
RNS Number : 0867G
Immupharma PLC
23 November 2020
23 November 2020
ImmuPharma plc
("ImmuPharma" or the "Company")
Conversion of Convertible Security
ImmuPharma plc (LSE:IMM) (Euronext Growth Brussels: ALIMM), the
specialist drug discovery and development company, announces that
L1 Capital Global Opportunities Master Fund ("L1") has converted
$200,000 (plus accrued but unpaid interest) of the convertible
security issued pursuant to the convertible security deed dated 10
June 2020, details of which were announced by the Company on 11
June 2020. The conversion price is 11p per share resulting in the
issue by the Company of 1,430,510 new ordinary shares of 10p each
in the Company ("New Ordinary Shares").
New Ordinary Shares and Admission
The New Ordinary Shares have been allotted today and are issued
credited as fully paid and will rank pari passu in all respects
with the Company's existing issued ordinary shares.
An application will be made for the New Ordinary Shares to be
admitted to trading on the AIM market of the London Stock Exchange
("AIM") and Euronext Growth Brussels ("Admission"). It is
anticipated that Admission to AIM will occur at 8.00am on or around
Thursday 26 November 2020.
The New Ordinary Shares represent 0.58% of the Company's
enlarged issued share capital.
Total Shares in Issue
For the purposes of the Disclosure Guidance and Transparency
Rules of the Financial Conduct Authority ("DTR"), the Board of
ImmuPharma hereby notifies the market that following Admission, the
Company's total issued share capital will consist of 247,716,315
Ordinary Shares with a nominal value of 10p each.
This figure may be used by Shareholders as the denominator for
the calculations by which they may determine if they are required
to notify their interest in, or a change to their interest in, the
Company under the DTR.
The allotment of the New Ordinary Shares is being made pursuant
to existing authorities to allot shares and other relevant
securities and to disapply pre-emption rights under section 551 of
the Companies Act 2006, which the Directors were given at the
Company's Annual General Meeting held on 18 June 2020.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information please contact:
ImmuPharma PLC ( www.immupharma.com )
Tim McCarthy, Chairman + 44 (0) 207 152 4080
Dimitri Dimitriou, Chief Executive Officer
Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin
Stanford Capital Partners (Joint Broker) +44 (0) 203 36 8 3550
Patrick Claridge
John Howes
Bob Pountney +44 (0) 203 815 8880
SI Capital (Joint Broker)
Nick Emerson +44 (0) 1483 413500
4Reliance (Euronext Growth Listing Sponsor) +32 (0) 2 747 02 60
Jean-Charles Snoy
Degroof Petercam (Liquidity Provider) +32 (0) 2 287 95 34
Erik De Clippel
Backstage Communication
Olivier Duquaine +32 (0) 477 504 784
Gunther De Backer +32 (0) 475 903 909
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a
specialty biopharmaceutical company that discovers and develops
peptide-based therapeutics. The Company's portfolio includes novel
peptide therapeutics for autoimmune diseases, anti-infectives,
metabolic diseases and cancer. The lead program, Lupuzor(TM), is a
first-in class autophagy immunomodulator which is in Phase III for
the treatment of systemic lupus erythematosus (lupus / SLE). Lupus
is an autoimmune disease which if left untreated can be fatal.
Preclinical analysis suggest therapeutic activity for many other
autoimmune diseases that share the same autophagy mechanism of
action. ImmuPharma and Avion Pharmaceuticals signed on 28 November
2019, an exclusive licence and development agreement and trademark
agreement for Lupuzor(TM) to fund a new international Phase III
trial for Lupuzor(TM) and commercialise in the US. For additional
information about ImmuPharma please visit www.immupharma.com.
ImmuPharma's LEI (Legal Entity Identifier) code:
213800VZKGHXC7VUS895.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CONEAAFFAEPEFFA
(END) Dow Jones Newswires
November 23, 2020 02:00 ET (07:00 GMT)
Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024